Accelerated Approval: Former ODAC Member Sekeres Reflects On Avastin Withdrawal
Executive Summary
Leukemia specialist Mikkael Sekeres’ new book, “Drugs and the FDA: Safety, Efficacy, and the Public’s Trust,” serves two purposes: a history of FDA oversight and regulation of drugs, as shaped by various public health crises and tragedies; and an insider's account of the June 2011 hearing on withdrawal of Avastin’s accelerated approval in breast cancer.
You may also be interested in...
CDER Opposes Covis’ Bid To Steer Focus Away From Makena's Failed Confirmatory Trial
The company offered to stipulate that findings from the PROLONG trial do not verify clinical benefit of the preterm birth prevention drug; the US FDA’s drugs center opposed a stipulation, saying failure of a confirmatory trial to verify clinical benefit is an independent ground for withdrawing accelerated approval and an advisory committee should vote on the question.
US Accelerated Approval: As Makena Withdrawal Hearing Looms, A Look Back At The Avastin Experience
With the public hearing on Covis’ drug for preterm birth prevention expected in 2022, the Pink Sheet talked to several former FDA officials and advisory committee members about their experiences at the 2011 hearing on withdrawal of Avastin’s accelerated approval for breast cancer.
Makena Withdrawal Hearing: US FDA Drugs Center, Covis Tussle Over Panel Composition
Practicing obstetricians who are maternal fetal-medicine specialists should make up a ‘significant proportion’ of the advisory committee at the forthcoming hearing, Covis says; CDER calls for a more ‘balanced’ panel that includes expertise in biostatistics, neonatology and epidemiology.